Stimulant and hallucinogenic novel psychoactive substances; an update
Fabrizio Schifano, Alessandro Vento, Norbert Scherbaum, Amira Guirguis
Expert Review of Clinical Pharmacology November 2, 2023 DOI: 10.1080/17512433.2023.2279192 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Stimulant Hallucinogen Pharmacology Traditional medicine |
| Citations | 30 |
| Key findings | An integrative research model combining pro-drug website analysis with computational chemistry is needed to organize preclinical studies of novel psychoactives, and psychedelic research requires robust study designs to evaluate therapeutic benefits. |
Abstract
Clinicians should be regularly informed about the range of NPS and their medical, psychobiological and psychopathological risks both in the acute and long term. Future research should focus on an integrative model in which pro-drug websites' analyses are combined with advanced research approaches, including computational chemistry studies so that in vitro and in vivo preclinical studies of index novel psychoactives can be organized. The future of psychedelic research should focus on identifying robust study designs to convincingly assess the potential therapeutic benefits of psychedelics, molecules likely to present with limited dependence liability levels.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cited by 7
- Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues. Brain Sciences April 22, 2025
- The role of mitochondrial dysfunction and calcium dysregulation in 2C-I and 25I-NBOMe-induced neurotoxicity. Chemico-Biological Interactions April 25, 2025
- Evaluation of Neurotoxicity of NBOH Derivatives Pharmaceuticals July 8, 2026
- [Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects]. Fortschritte der Neurologie · Psychiatrie June 8, 2026
- An Update on the Epidemiology of Tusi ("Pink Cocaine"). Current Addiction Reports 2025
and 2 more in the library
Cites 68
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Psychedelics, Meditation, and Self-Consciousness Frontiers in Psychology September 4, 2018
- Novel psychoactive substances of interest for psychiatry World Psychiatry February 1, 2016
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Recreational Use, Analysis and Toxicity of Tryptamines Current Neuropharmacology December 10, 2014
and 63 more in the library